Clinical efficacy of lentinan on patients with stomach cancer

Taguchi, T; Furue, H; Kimura, Tadashi; Kondoh, Taiji; Hattori, Tatsuo; Ogawa, Narihito

doi:10.1016/0192-0561(85)90264-4

Cited by 17 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prolongation of patient's survival was linked to increased infiltration of T cells, B cells and macrophages in tumor, prevention of metastasis and restoration of T helper 1 to T helper 2 balance [213,217,224]. However, the clinical trials show that polysaccharide BRMs are only effective when administered at early cancer stages rather than advanced cancer stage [211][212][213][214][215][216][217][218][219][220][221][222].…”

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

“…For i.v. injection, the dose employed was as high as 2 mg weekly [212], and the oral dose employed was as high as 3 mg/day [217]. The clinical trials reported no adverse effects with the administration of the polysaccharides.…”

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

“…However, the therapeutic data are mainly derived from the study of animal models such as mouse [7,8,67,73,95,157,169,170,195,196,200,[203][204][205]207], cat [195], chicken [159] and pig [198] and [208]. In fact, clinical data are limited and most of the studies were performed in oriental countries like China [209] and Japan [210][211][212][213][214][215][216][217][218]. Clinical data are restricted to the application of Lentinan (LNT) [210,212,213,216,219,220], protein-bound polysaccharide (PSK) [214,217,218,[221][222][223], polysaccharide peptide (PSP) [209] and schizophyllan (SPG) [211] in tumor immunotherapy.…”

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

“…Clinical data are restricted to the application of Lentinan (LNT) [210,212,213,216,219,220], protein-bound polysaccharide (PSK) [214,217,218,[221][222][223], polysaccharide peptide (PSP) [209] and schizophyllan (SPG) [211] in tumor immunotherapy. These polysaccharide BRMs were mainly used as adjuvant in post-operative treatment [218], chemotherapy [210,212,214,[217][218][219][220][221][222] radiotherapy [211] and [215], radiochemotherapy [215] and endocrine therapy [213,219] of different cancers such as breast cancer [213], cervical cancer [211], colorectal cancer [214,217,218,223], gastrointestinal cancer [210,220], lung cancer [209,217,222] and prostate cancer [219]. The clinical trials demonstrated the polysaccharide BRMs can prolong the survival and improve the quality of life of the patients.…”

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

See 3 more Smart Citations

Polysaccharide biological response modifiers

et al. 2006

View full text Add to dashboard Cite

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

Section: Clinical Applications Of Brmsmentioning

confidence: 99%

See 2 more Smart Citations

Polysaccharide biological response modifiers

et al. 2006

View full text Add to dashboard Cite

“…Lentinan, a fungal branched (1...3)-beta-D-glycan, has a BRM function and has been used in the treatment of cancer patients, especially digestive-cancer patients [41,42]. Both T cell and macrophage functions have been stimulated by lentinan, as well as the production of var ious cytokines such as IL-1, IL-3 and IFN-y [43][44][45].…”

Section: Introductionmentioning

confidence: 99%

Effects of OK-432 (Picibanil) on the Estrogen Receptors of MCF-7 Cells and Potentiation of Antiproliferative Effects of Tamoxifen in Combination with OK-432

et al. 1997

View full text Add to dashboard Cite

OK-432 (picibanil), a streptococcal preparation, has a strong biological response modifier (BRM) function and is expected to produce clinical improvement and prolongation of survival in treated cancer patients in Japan. We were interested in whether OK-432 augments estrogen receptor (ER) levels in breast cancer. To investigate the effect of the BRMs on cellular growth and the characteristics of ER and progesterone receptors (PgR) in the human breast cancer cell line MCF-7, we used OK-432, Krestin (PSK), a protein-bound polysaccharide extracted from Coriolus versicolor, and lentinan, a fungal branched (1 ...3)-beta-Z)-glycan. OK432 and PSK dose dependently inhibited DNA synthesis of MCF-7 cells, and the 50% inhibitory concentrations of OK-432 and PSK were 1.2 KE (klinische Einheit, clinical unit)/ml and 200 ug/ml, respectively. Lentinan showed no direct anticancer effect in vitro. We found that OK-432 induced a 2-fold increase in ER levels in MCF-7 cells at 0.005 KE/ml, but not in PgR. Lentinan and low-dose PSK did not change ER or PgR levels, but high-dose PSK decreased ER and PgR. We also studied the combined effect of OK-432 and antiestrogens, tamoxifen (TAM) and DP-TAT-59. The combined treatment with OK-432 and TAM showed an additive inhibitory effect on MCF-7 cells. These results suggest that OK-432 may augment the therapeutic effect of TAM in breast cancer.

show abstract

Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta‐analysis

et al. 2017

View full text Add to dashboard Cite

Lentinan is a common biological response modifier. This study was sought to evaluate the efficacy of adjuvant lentinan combined with chemotherapy for advanced cancer. A meta‐analysis of published prospective controlled trials investigating the effects of lentinan for kinds of advanced cancer was performed. Sensitivity analysis, inverted funnel plots, and trial sequence analysis were conducted to explore the reliability and stability of results. Seventeen clinical studies were identified containing 1423 patients. Twelve trials included gastrointestinal cancer (GIC), three trials included lung cancer (LC), and two trials included the two cancers. There was a increase in survival rate in 1 year (risk ratios [RR], 1.46, P = 0.001) and overall response rate including both complete and partial response (RR, 1.28, P = 0.005). There was also a reduction in progressive disease (RR, 0.57, P = 0.0005), nonsevere adverse events (RR, 0.88, P = 0.004), and severe adverse events (RR, 0.73, P = 0.007). Similar results were shown in the two subgroups of GIC and LC. Limited trials reported the data of median overall survival and time to treatment failure, and the data were insufficient for quantitative analysis, and no significant difference were found in 2‐year survival rate. Adjuvant lentinan used with chemotherapy achieved improvements in 1‐year survival rate, response rate, and adverse events in advanced cancer. The effect seemed to be similar irrespective of cancer type. However, its sustained efficacy on survival was still unclear.

show abstract

Clinical efficacy of lentinan on patients with stomach cancer

Cited by 17 publications

References 0 publications

Polysaccharide biological response modifiers

Polysaccharide biological response modifiers

Effects of OK-432 (Picibanil) on the Estrogen Receptors of MCF-7 Cells and Potentiation of Antiproliferative Effects of Tamoxifen in Combination with OK-432

Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta‐analysis

Contact Info

Product

Resources

About